Cargando…

Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study

BACKGROUND: Malignant pleural mesothelioma (MPM) is an incurable, late presenting primary cancer, conferring a survival of 8–14 months. Different intrapleural treatments have been tested as part of a multimodality approach to treat a select group of patients with limited disease, increasing survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Bille, Andrea, Jhala, Hiral, Ashrafian, Leanne, Allison, Leanne, Russell, Matthew, Fleck, Roland, Nonaka, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413027/
https://www.ncbi.nlm.nih.gov/pubmed/37577311
http://dx.doi.org/10.21037/tlcr-22-282
_version_ 1785087045230657536
author Bille, Andrea
Jhala, Hiral
Ashrafian, Leanne
Allison, Leanne
Russell, Matthew
Fleck, Roland
Nonaka, Daisuke
author_facet Bille, Andrea
Jhala, Hiral
Ashrafian, Leanne
Allison, Leanne
Russell, Matthew
Fleck, Roland
Nonaka, Daisuke
author_sort Bille, Andrea
collection PubMed
description BACKGROUND: Malignant pleural mesothelioma (MPM) is an incurable, late presenting primary cancer, conferring a survival of 8–14 months. Different intrapleural treatments have been tested as part of a multimodality approach to treat a select group of patients with limited disease, increasing survival. Recently, povidone-iodine has been shown to induce apoptosis in microscopic tumour cells in vitro, with no reported complications. This is the first in vivo study assessing the apoptotic rate caused by intraoperative hyperthermic betadine lavage using routine immunohistochemistry combined with transmission electron microscopy (TEM). METHODS: We included surgically fit patients aged >18, undergoing minimally invasive video-assisted thoracoscopic surgery (VATS) pleural biopsy between December 2016 and February 2018, for confirmed or presumed pleural malignancy. Parietal pleural biopsies were obtained at 7.5, 15 and 30 minutes after hyperthermic betadine lavage, and compared to pre-lavage biopsy samples, for apoptotic changes. Viable tumour samples underwent histological, immunohistochemical and ultrastructural analysis as well as TEM for features of apoptosis. RESULTS: N=6. Median age was 76 years. Median overall survival was 26.7 months. There was no statistical impact on survival of side of disease (left vs. right). There was no significant difference in expressions of markers of apoptotic index pre and post betadine treatment upon immunohistochemical analysis. There was no discernible effect on morphological features of apoptosis seen with betadine treatment, on TEM analysis. No side effects were identified post betadine lavage. CONCLUSIONS: Although hyperthermic betadine lavage is a safe antiseptic solution with no toxicity when performed intraoperatively, it confers no effect on apoptotic rate or necrosis. It is therefore unlikely that hyperthermic betadine lavage will have an impact on reducing the microscopic residual disease after pleurectomy decortication and enhancing survival.
format Online
Article
Text
id pubmed-10413027
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-104130272023-08-11 Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study Bille, Andrea Jhala, Hiral Ashrafian, Leanne Allison, Leanne Russell, Matthew Fleck, Roland Nonaka, Daisuke Transl Lung Cancer Res Original Article BACKGROUND: Malignant pleural mesothelioma (MPM) is an incurable, late presenting primary cancer, conferring a survival of 8–14 months. Different intrapleural treatments have been tested as part of a multimodality approach to treat a select group of patients with limited disease, increasing survival. Recently, povidone-iodine has been shown to induce apoptosis in microscopic tumour cells in vitro, with no reported complications. This is the first in vivo study assessing the apoptotic rate caused by intraoperative hyperthermic betadine lavage using routine immunohistochemistry combined with transmission electron microscopy (TEM). METHODS: We included surgically fit patients aged >18, undergoing minimally invasive video-assisted thoracoscopic surgery (VATS) pleural biopsy between December 2016 and February 2018, for confirmed or presumed pleural malignancy. Parietal pleural biopsies were obtained at 7.5, 15 and 30 minutes after hyperthermic betadine lavage, and compared to pre-lavage biopsy samples, for apoptotic changes. Viable tumour samples underwent histological, immunohistochemical and ultrastructural analysis as well as TEM for features of apoptosis. RESULTS: N=6. Median age was 76 years. Median overall survival was 26.7 months. There was no statistical impact on survival of side of disease (left vs. right). There was no significant difference in expressions of markers of apoptotic index pre and post betadine treatment upon immunohistochemical analysis. There was no discernible effect on morphological features of apoptosis seen with betadine treatment, on TEM analysis. No side effects were identified post betadine lavage. CONCLUSIONS: Although hyperthermic betadine lavage is a safe antiseptic solution with no toxicity when performed intraoperatively, it confers no effect on apoptotic rate or necrosis. It is therefore unlikely that hyperthermic betadine lavage will have an impact on reducing the microscopic residual disease after pleurectomy decortication and enhancing survival. AME Publishing Company 2023-07-14 2023-07-31 /pmc/articles/PMC10413027/ /pubmed/37577311 http://dx.doi.org/10.21037/tlcr-22-282 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Bille, Andrea
Jhala, Hiral
Ashrafian, Leanne
Allison, Leanne
Russell, Matthew
Fleck, Roland
Nonaka, Daisuke
Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title_full Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title_fullStr Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title_full_unstemmed Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title_short Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
title_sort does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413027/
https://www.ncbi.nlm.nih.gov/pubmed/37577311
http://dx.doi.org/10.21037/tlcr-22-282
work_keys_str_mv AT billeandrea doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT jhalahiral doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT ashrafianleanne doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT allisonleanne doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT russellmatthew doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT fleckroland doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy
AT nonakadaisuke doeshyperthermicpovidoneiodinelavageincreasetheapoptoticrateofresidualcancercellinpatientswithmalignantpleuralmesotheliomaaprospectivepilotstudy